RT Journal Article
SR Electronic
T1 Kinetics of naturally induced binding and neutralizing anti-SARS-CoV-2 antibody levels and potencies among Kenyan patients with diverse grades of COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.05.22280716
DO 10.1101/2022.10.05.22280716
A1 Kimotho, John
A1 Sein, Yiakon
A1 Sayed, Shahin
A1 Shah, Reena
A1 Mwai, Kennedy
A1 Saleh, Mansoor
A1 Wanjiku, Perpetual
A1 Mwacharo, Jedidah
A1 Nyagwange, James
A1 Karanja, Henry
A1 Kutima, Bernadette
A1 Gitonga, John
A1 Mugo, Daisy
A1 Karanu, Ann
A1 Moranga, Linda
A1 Oluoch, Vivian
A1 Shah, Jasmit
A1 Mutiso, Julius
A1 Mburu, Alfred
A1 Nneka, Zaitun
A1 Betti, Peter
A1 Mutinda, Wanzila Usyu
A1 Abdi, Abdirahman Issak
A1 Bejon, Philip
A1 Ochola-Oyier, Lynette Isabella
A1 Warimwe, George M.
A1 Nduati, Eunice
A1 Ndungu, Francis M.
YR 2022
UL http://medrxiv.org/content/early/2022/10/05/2022.10.05.22280716.abstract
AB Background Given the low levels of COVID-19 vaccine coverage in Sub-Saharan Africa, despite high levels of natural SARS-CoV-2 exposures, strategies for extending the breadth and longevity of naturally acquired immunity are warranted. Designing such strategies will require a good understanding of natural immunity.Methods We used ELISA to measure whole-spike IgG and spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months of COVID-19 diagnosis in 309 COVID-19 patients. We measured antibody neutralizing potency against the wild-type (Wuhan) SARS-CoV-2 pseudo-virus in a subset of 51 patients over three successive time points. Binding and neutralizing antibody levels and potencies were then tested for correlations with COVID-19 severities, graded according to the National Institute of Health (NIH), USA criteria.Results Rates of sero-conversion increased from Day 0 (day of PCR testing) to Day 180 (six months) (63.6% to 100 %) and (69.3 % to 97%) for anti-spike IgG and anti-spike-RBD binding Igs, respectively. Levels of these binding antibodies peaked at Day 28 (P<0.0001) and were subsequently maintained for six months without significant decay (p>0.99). Similarly, antibody neutralizing potencies peaked at Day 28 (p<0.0001) but had decreased by three-folds, six months after COVID-19 diagnosis (p<0.0001). Binding antibodies levels were highly correlated with neutralizing antibody potencies at all the time points analyzed (r>0.6, P<0.0001). Levels and potencies of binding and neutralizing antibodies increased with disease severity.Conclusion Most COVID-19 patients from Sub-Saharan Africa generate SARS-CoV-2 specific binding antibodies that remain stable during the first six months of infection. Although antibody binding levels and neutralizing potencies were directly correlated, the respective neutralizing antibodies decayed three-fold by the sixth month of COVID-19 diagnosis suggesting that they are short-lived, consistent with what has been observed elsewhere. Thus, just like for other populations, regular vaccination boosters will be required to broaden and sustain the high levels of predominantly naturally acquired anti-SARS-CoV-2 neutralizing antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by EDCTP grant number RIA2020EF-3042.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Kenya Medical Research Institute gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://doi.org/10.7910/DVN/6KW9U1 https://doi.org/10.7910/DVN/6KW9U1 AEUArbitrary ELISA unitsBAUBinding antibody unitsCOVID-19Corona virus disease 2019CtCycle thresholdELISAEnzyme-linked immuno-sorbent assayHRPHorseradish peroxidase; Immunoglobulin GIgMImmunoglobulin MIgAImmunoglobulin AIgImmunoglobulinID5050% inhibitory dilutionODOptical densityOPDo-PhenylenediaminePBSPhosphate buffered saline; Room temperatureRT-PCRReverse transcription polymerase chain reactionRBDReceptor binding domainRLUsRelative light unitsSARS-CoV-2severe acute respiratory syndrome coronavirus 2WASP-HRPWiskott-Aldrich syndrome protein - Horseradish peroxidase;